Published November 15, 2012 | Version v1
Journal article

Five-year Local Control in a Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy With an Incorporated Boost for Early Stage Breast Cancer

  • 1. Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania (United States)
  • 2. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (United States)
  • 3. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (United States)
  • 4. Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania (United States)
  • 5. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (United States)
  • 6. School of Nursing, Emory University, Atlanta, Georgia (United States)
  • 7. Department of Surgical Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York (United States)

Description

Purpose: Conventional radiation fractionation of 1.8-2 Gy per day for early stage breast cancer requires daily treatment for 6-7 weeks. We report the 5-year results of a phase II study of intensity modulated radiation therapy (IMRT), hypofractionation, and incorporated boost that shortened treatment time to 4 weeks. Methods and Materials: The study design was phase II with a planned accrual of 75 patients. Eligibility included patients aged ≥18 years, Tis-T2, stage 0-II, and breast conservation. Photon IMRT and an incorporated boost was used, and the whole breast received 2.25 Gy per fraction for a total of 45 Gy, and the tumor bed received 2.8 Gy per fraction for a total of 56 Gy in 20 treatments over 4 weeks. Patients were followed every 6 months for 5 years. Results: Seventy-five patients were treated from December 2003 to November 2005. The median follow-up was 69 months. Median age was 52 years (range, 31-81). Median tumor size was 1.4 cm (range, 0.1-3.5). Eighty percent of tumors were node negative; 93% of patients had negative margins, and 7% of patients had close (>0 and <2 mm) margins; 76% of cancers were invasive ductal type: 15% were ductal carcinoma in situ, 5% were lobular, and 4% were other histology types. Twenty-nine percent of patients 29% had grade 3 carcinoma, and 20% of patients had extensive in situ carcinoma; 11% of patients received chemotherapy, 36% received endocrine therapy, 33% received both, and 20% received neither. There were 3 instances of local recurrence for a 5-year actuarial rate of 2.7%. Conclusions: This 4-week course of hypofractionated radiation with incorporated boost was associated with excellent local control, comparable to historical results of 6-7 weeks of conventional whole-breast fractionation with sequential boost.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2012.01.091

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2012.01.091;
PII
S0360-3016(12)00201-5;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
84
Journal Issue
4
Journal Page Range
p. 888-893
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
44104291
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; CHEMOTHERAPY; FRACTIONATION; HISTOLOGY; MAMMARY GLANDS; PATIENTS; PHOTONS; RADIOTHERAPY
Descriptors DEC
BODY; BOSONS; DISEASES; ELEMENTARY PARTICLES; GLANDS; MASSLESS PARTICLES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; SEPARATION PROCESSES; THERAPY

Optional Information

Copyright
Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.